31.05.2019

Neovii & Mundipharma Confirm In-licensing Agreement

Neovii & Mundipharma Confirm In-licensing Agreement for the Development and Promotion of Grafalon(R) in China and Japan for Solid Organ & Stem Cell Transplant

Neovii and Mundipharma have entered into an agreement giving Mundipharma the rights to develop and distribute its polyclonal antibody immunosuppressant Grafalon®, in China and Japan from end October 2018.

Grafalon® is currently approved for prevention of rejection and the treatment of acute steroid resistant rejection in solid organ transplant in China. Under its license, Mundipharma intends to strengthen the distribution and support of Grafalon® in these key markets to advance the clinical development for the prevention of chronic GvHD in SCT.

Juergen Pohle, Neovii CEO commented, “We are very enthusiastic to work with Mundipharma as a partner to develop Grafalon® in China further by developing its indication for use in stem cell transplantation and further solidifying the position of Grafalon® as a leading treatment for solid organ transplant patients in China.” 

Mundipharma CEO, Raman Singh, said, “We are excited to establish a partnership with Neovii that will have a positive impact on patients in China and Japan, who will have access to the leading technology for prevention of GvHD.”

“We view Grafalon® as a strategic complement to our existing haemotology and oncology franchise,” he added. “SCT continues to be the only curative therapy for many patients with leukemia, lymphoma, and Grafalon® has the potential to help

About Mundipharma

Mundipharma is a network of independent associated companies which are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma is a prime example of an organization that consistently delivers high-quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

For more information please visit: Mundipharma.com